Follow the Money: Inside the Collapse of Lydac Neuroscience

The Men Behind Wellbeing — Chapter Eight

Lydac Neuroscience was the company historically associated with Stephen Ray’s microvesicle intellectual property. Andrew Chancellor later became its director. In December 2018, the company entered administration. To understand what happened to the science, we first need to understand what happened to the company—and, crucially, its assets.

Chapter Seven established the chronology.

Stephen Ray was involved with Lydac Neuroscience from its incorporation.

His microvesicle research became associated with intellectual property held by the company.

Ray later left.

Andrew Chancellor subsequently became a director.

Then Lydac failed.

Companies House confirms that Lydac Neuroscience Limited, company number 06369154, was incorporated in September 2007 as a biotechnology research company and was ultimately dissolved on 9 April 2025. (Find and Update Company Information)

But between those two dates lies the part of the story that matters most.

The insolvency.

Because when a biotechnology company collapses, the company itself may disappear while its most important assets survive.

Patents can be sold.

Licences can be transferred.

Research can continue elsewhere.

Know-how can move with scientists.

Intellectual property can be acquired by another organisation.

That means the failure of Lydac does not necessarily mark the end of Stephen Ray's microvesicle technology.

It may instead mark the point at which we need to start following its ownership.

17 December 2018: Administrators Take Control

The official Gazette records that administrators were appointed to Lydac Neuroscience on 17 December 2018.

They were:

Ian Robert

and

Christopher Purkiss

of Kingston Smith & Partners LLP.

The Gazette describes Lydac's nature of business as:

“Research and experimental development on biotechnology.”

Its registered office and principal trading address were both recorded as 10 Harley Street, London W1G 9PF. (The Gazette)

This is important.

Lydac was not simply removed from Companies House because somebody stopped filing paperwork.

It entered a formal insolvency procedure.

Administrators took control.

And from this point, the company's assets, liabilities and creditors became part of an insolvency process.

For this investigation, that creates one overriding question:

What assets did Lydac actually have when the administrators arrived?

Why Did a Dormant Company Need Administrators?

There is an apparent contradiction in Lydac's history that deserves examination.

Companies House records show dormant-company accounts for the financial years ending 30 September 2015, 2016 and 2017. (Companies in the UK)

Yet in December 2018 the company entered administration.

That does not establish anything improper.

A company can legitimately hold intellectual property while carrying out little or no accounting activity. Research, licensing or commercial operations can also sit elsewhere in a corporate structure.

But it does create an obvious question:

What financial obligations existed by December 2018 that required Lydac to enter administration?

That answer matters.

Because it potentially tells us what the company had been doing, who had funded it and what remained when it failed.

The Statement of Affairs

The first document we need to examine closely was filed on 28 January 2019.

Companies House records a nine-page:

Statement of Affairs in Administration. (Companies in the UK)

For an investigation into a failed company, this is potentially gold dust.

A statement of affairs can provide a snapshot of the company's financial position around insolvency.

It can identify assets.

It can identify creditors.

It can show liabilities.

And it can show what those assets were expected to realise.

For Lydac, however, I am particularly interested in one category.

Intellectual property.

Where Was Stephen Ray's Intellectual Property?

We already know from patent records that Lydac was associated with Stephen Ray's microvesicle technology.

And this was not merely a European filing.

An official Canadian patent publication from 2019 also identifies Lydac Neuroscience Limited against Canadian patent 2,711,218. (Publications.gc.ca)

So when the administrators arrived, we need to establish:

Was this intellectual property still owned by Lydac?

Was it listed as an asset?

Was a value attributed to it?

Had it been licensed?

Had some territorial rights lapsed?

Had any rights already been transferred elsewhere?

Or did the administrators consider the patents to have little or no realisable value?

Those questions are central to what comes next.

9 April 2019: The Administrator's Proposal

A much larger document followed.

On 9 April 2019, the company's filing history records a 31-page Administrator's Proposal. The insolvency record also shows a creditors' decision immediately afterwards and a later administrator's progress report. (Companies in the UK)

This document matters because administrators do not write company biographies for publicity.

Their purpose is very different.

They need to explain the financial position and what they propose doing about it.

That means this report potentially contains the contemporary professional account of what went wrong at Lydac.

Not someone's recollection years later.

Not marketing.

Not an interview.

An insolvency report prepared while the company was actually in administration.

Follow the Creditors

The existence of a formal creditors' process raises another important question.

Who was owed money?

This is an area where we need to resist speculation.

An administration does not automatically mean investors lost money.

It does not automatically mean directors owed money.

And it certainly does not establish wrongdoing.

We need the documents.

But once the creditor schedules are established, we can start asking more precise questions.

Were creditors suppliers?

Professional advisers?

Patent attorneys?

Directors?

Shareholders?

Connected companies?

Research partners?

Private lenders?

Or people who had funded the biotechnology venture?

The answer could tell us considerably more about how Lydac had actually been financed.

19 July 2019: The Progress Report

Several months later, another significant filing appeared.

On 19 July 2019, Companies House records an Administrator's Progress Report.

It ran to 17 pages.

By this point, administrators had been controlling Lydac for approximately seven months.

This document is particularly interesting because by then they had had time to investigate the company's affairs and attempt to realise assets.

And that brings us straight back to the patents.

Were the Patents Sold?

Suppose Lydac still owned commercially useful intellectual property when it entered administration.

The administrators would then have had to determine what could be done with it.

Potentially:

sell it;

license it;

package it with other assets;

allow rights to lapse;

or conclude that it had little realisable value.

If a sale occurred, there should potentially be a purchaser.

If a licence was sold or assigned, there should potentially be a counterparty.

If intellectual property had already left Lydac before administration, that creates a different question:

When did it leave—and where did it go?

This is the point at which the insolvency investigation begins to connect directly with Wellbeing International Foundation.

15 November 2019: Administration Ends

Administration did not restore Lydac as an operating biotechnology company.

On 15 November 2019, Lydac moved into creditors' voluntary liquidation.

The Gazette records Ian Robert and Christopher Purkiss as the liquidators and specifically records the appointment as a paragraph 83 exit from administration. (The Gazette)

The distinction matters.

The company was now being wound up.

Whatever viable business Lydac once represented was not continuing through that corporate entity.

But the liquidation itself continued for years.

Six More Years Before Lydac Finally Disappeared

The company's filing history records liquidators' statements of receipts and payments through subsequent years, including statements covering 2021, 2022 and 2023.

A final creditors' voluntary winding-up return was filed in January 2025.

Then, on:

9 April 2025

Lydac Neuroscience Limited was formally dissolved. (Companies in the UK)

That is almost six and a half years after administrators were first appointed.

Why did the winding-up take that long?

The answer may be routine.

Complex insolvencies can take years.

But those receipts-and-payments reports are nevertheless important because they potentially tell us what money came into the liquidation and where it went.

The Company Died. Intellectual Property Doesn't Necessarily Die With It.

This is the distinction at the centre of our investigation.

When a restaurant collapses, we might follow its premises, equipment and stock.

When a biotechnology company collapses, some of its potentially most valuable assets can be invisible.

Patents.

Patent applications.

Licences.

Research data.

Laboratory protocols.

Manufacturing methods.

Scientific know-how.

Those assets can survive the company that originally owned them.

And sometimes they become the foundations of something else.

That is why we cannot stop at the words:

“Lydac Neuroscience — Dissolved.”

We have to determine what survived it.

This Is Where Andrew Chancellor Becomes Relevant

Andrew Chancellor was a director of Lydac when the company entered administration.

That fact requires careful treatment.

It does not establish that Chancellor caused the insolvency.

It does not establish that he improperly transferred assets.

It does not establish that he personally acquired intellectual property.

And I have not seen evidence establishing misconduct by Chancellor in relation to Lydac's insolvency.

Those would be serious allegations and should not be made without evidence.

But Chancellor's position nevertheless matters.

He was directing Lydac during the later part of its corporate life.

And today he is Chief Executive of Wellbeing International Foundation.

That makes a perfectly legitimate question possible:

What happened to the scientific assets of the company Chancellor previously directed?

And Stephen Ray Remains Central

Stephen Ray was no longer a Lydac director when administrators arrived.

He had left years earlier.

So again, we should not imply responsibility for an insolvency that occurred long after his directorship ended.

But Ray remains central for another reason.

He was the inventor.

The microvesicle patents take us back to his science.

Today, Ray appears again within Wellbeing's scientific operation.

So if the technology continued after Lydac, we need to distinguish between two very different things:

the scientist's continuing knowledge

and

the legal ownership of intellectual property previously assigned to a company.

Those are not the same.

An inventor can continue being an expert in his invention after ownership of a patent has passed elsewhere.

That is precisely why we need the ownership records.

Now Remember Why We Are Investigating This

This is where we must reconnect the story to Wellbeing.

We are not spending chapters investigating a defunct biotechnology company simply because it failed.

The reason Lydac matters is that the people and science appearing in its history appear again in the Wellbeing story.

Stephen Ray.

Andrew Chancellor.

Microvesicle and extracellular-vesicle science.

And now an organisation presenting Cell-Free Therapy to patients and seeking investment.

That creates an important question of provenance.

If Wellbeing's current technology substantially developed from the science previously commercialised through Lydac, what happened between the two organisations?

There may be a perfectly legitimate answer.

But we need to find it.

An Insolvency Could Actually Make That Question More Important

Imagine that Lydac owned relevant patents when it became insolvent.

Those patents were company assets.

They were not automatically Andrew Chancellor's property.

They were not automatically Stephen Ray's property simply because he invented the technology.

And they certainly would not automatically become Wellbeing's property because Ray and Chancellor later worked there.

There would need to be a legal explanation for any transfer of ownership or rights.

Perhaps there was one.

Perhaps the patents were sold.

Perhaps they were licensed.

Perhaps later intellectual property replaced them.

Perhaps Wellbeing's technology is materially different.

Perhaps the original patents ceased to be relevant.

All are possible.

But this is exactly what we now need to establish.

And Then There Is the Investor

This is where the historical insolvency becomes a present-day issue.

If an organisation seeks investment around biotechnology, an investor should understand the intellectual property underpinning that opportunity.

That means asking:

What patents exist?

Who owns them?

What licences exist?

Which company owns the technology?

What intellectual property is actually proprietary?

How long does the protection last?

And what happens if the historical technology originated inside another company?

This isn't an accusation.

It is biotechnology due diligence.

What We Know

The documentary position at this stage is relatively straightforward.

Lydac Neuroscience was a biotechnology company.

It was historically associated with Stephen Ray's microvesicle intellectual property.

Andrew Chancellor later became a director.

Lydac entered administration on 17 December 2018. (The Gazette)

A Statement of Affairs was filed.

An Administrator's Proposal followed.

A Progress Report followed.

The company left administration and entered creditors' voluntary liquidation on 15 November 2019. (The Gazette)

The liquidation continued for years.

And Lydac was finally dissolved on 9 April 2025. (Find and Update Company Information)

Those facts are established.

What We Don't Know

This part is equally important.

We have not yet established the total creditor shortfall.

We have not yet established whether investors lost money or, if so, how much.

We have not established that Lydac's patents were sold during administration.

We have not established that Chancellor acquired them.

We have not established that Ray reacquired them.

We have not established that Wellbeing acquired them.

And we have not established that Wellbeing's current Cell-Free Therapy is legally or technically the same invention covered by the Lydac patent family.

Until the documents establish those things, we should not state them as facts.

But We Now Know Exactly What We Need

This is the breakthrough.

The investigation no longer needs to ask vaguely:

“What happened to Lydac?”

We know where the answers should be.

The Statement of Affairs.

The Administrator's Proposal.

The Administrator's Progress Report.

The transition into liquidation.

The liquidators' receipts-and-payments statements.

And alongside all of them:

the complete patent-assignment history.

Put those documents together and we should be able to start reconstructing what happened to Lydac's assets.

And if those assets included Stephen Ray's microvesicle technology, we can start following where the science went next.

Conclusion: Follow the Money — Then Follow the Science

The corporate history of Lydac Neuroscience has an ending.

9 April 2025.

Dissolved.

But the scientific story does not end there.

Stephen Ray's work continued.

Andrew Chancellor's involvement in biotechnology continued.

And today both men appear within Wellbeing International Foundation.

That does not prove that Lydac's intellectual property moved to Wellbeing.

But it gives us a compelling reason to establish whether it did.

Because if Wellbeing's Cell-Free Therapy is genuinely new and independent of Lydac's intellectual property, the evidence should eventually allow us to separate the two.

If it evolved from Ray's earlier technology, we should be able to trace that evolution.

And if intellectual property moved from an insolvent company into another commercial structure, we should be able to identify the legal mechanism through which it moved.

The next chapter therefore returns directly to the organisation at the centre of this investigation.

Because after following the people, the patents and now the insolvency, we arrive at the question that matters to both patients and prospective investors:

What science does Wellbeing International Foundation actually own?

Next: Chapter Nine — The Missing Asset: Does Wellbeing Actually Own the Science Behind Cell-Free Therapy?

Lydac disappeared. The science apparently didn't. In Chapter Nine, we compare Stephen Ray's historical microvesicle intellectual property with the Cell-Free Therapy promoted by Wellbeing today. If the two share the same technological lineage, we ask the question investors should be asking before putting in a penny: where is the ownership trail, and what does Wellbeing actually own?